Pureos Bioventures, a newly formed venture capital firm, will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies. The firm is advised by Bellevue Asset Management.
The fund BB Pureos Bioventures LP (“Pureos”) was closed with committed capital of USD 170 million. The supporters of the first Pureos fund include strategic limited partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, and family offices, institutional investors, and fund-of-funds.
For its first fund, Pureos is building a balanced portfolio of 15-20 pre-clinical and clinical-stage companies. Its initial investments include the Swiss start-ups Alentis Therapeutics AG and NovaGo Therapeutics AG as well as AM-Pharma BV, Eyevensys SAS, Imcheck Therapeutics SAS, Lava Therapeutics BV and Vico Therapeutics BV. Company building is an important part of Pureos. It is a Partner of BaseLaunch, a start-up accelerator in Basel and together with a team of Entrepreneurs-in-Residence, Pureos is working on translating ground-breaking science into novel companies.
Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies. The fund’s portfolio companies are built on scientific excellence with strong teams to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. The fund invests globally, with a primary focus on Switzerland and Europe. The Pureos team consists of experienced venture capitalists, biotech entrepreneurs, and drug developers.
(Press release / SK)
0Comments
Please login or sign up to comment.
Commenting guidelines